Paolo Denti
Title
Cited by
Cited by
Year
Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests
C Cobelli, GM Toffolo, CD Man, M Campioni, P Denti, A Caumo, P Butler, ...
American Journal of Physiology-Endocrinology and Metabolism 293 (1), E1-E15, 2007
3462007
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampicin concentrations: dosing implications
E Chigutsa, ME Visser, EC Swart, P Denti, S Pushpakom, D Egan, ...
Antimicrobial agents and chemotherapy, AAC. 01833-10, 2011
1232011
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines
H McIlleron, R Rustomjee, M Vahedi, T Mthiyane, P Denti, C Connolly, ...
Antimicrobial agents and chemotherapy 56 (6), 3232-3238, 2012
942012
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection
KE Dooley, P Denti, N Martinson, S Cohn, F Mashabela, J Hoffmann, ...
The Journal of infectious diseases 211 (2), 197-205, 2015
842015
Characterizing multisegment foot kinematics during gait in diabetic foot patients
Z Sawacha, G Cristoferi, G Guarneri, S Corazza, G Donà, P Denti, ...
Journal of neuroengineering and rehabilitation 6, 37, 2009
752009
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.
P Denti, K Jeremiah, E Chigutsa, D Faurholt-Jepsen, G PrayGod, ...
PloS one 10 (10), e0141002, 2015
582015
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction
MT Chirehwa, R Rustomjee, T Mthiyane, P Onyebujoh, P Smith, ...
Antimicrobial agents and chemotherapy 60 (1), 487-494, 2016
562016
Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV
K Jeremiah, P Denti, E Chigutsa, D Faurholt-Jepsen, G PrayGod, ...
Antimicrobial agents and chemotherapy 58 (6), 3468-3474, 2014
552014
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
SP Zvada, P Denti, PR Donald, HS Schaaf, S Thee, JA Seddon, HI Seifart, ...
Journal of Antimicrobial Chemotherapy 69 (5), 1339-1349, 2014
462014
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients
SP Zvada, P Denti, FA Sirgel, E Chigutsa, M Hatherill, S Charalambous, ...
Antimicrobial agents and chemotherapy 58 (1), 503-510, 2014
392014
Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis
N Rockwood, JG Pasipanodya, P Denti, F Sirgel, M Lesosky, T Gumbo, ...
Clinical Infectious Diseases 64 (10), 1350-1359, 2017
382017
Antimalarial and anticancer activities of artemisinin–quinoline hybrid-dimers and pharmacokinetic properties in mice
MC Lombard, DD N’Da, JC Breytenbach, NI Kolesnikova, CT Van Ba, ...
European Journal of Pharmaceutical Sciences 47 (5), 834-841, 2012
372012
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in …
K Singh, J Okombo, C Brunschwig, F Ndubi, L Barnard, C Wilkinson, ...
Journal of medicinal chemistry 60 (4), 1432-1448, 2017
352017
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture
E Chigutsa, K Patel, P Denti, M Visser, G Maartens, CMJ Kirkpatrick, ...
Antimicrobial agents and chemotherapy 57 (2), 789-795, 2013
352013
UCT943, a next-generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria
C Brunschwig, N Lawrence, D Taylor, E Abay, M Njoroge, GS Basarab, ...
Antimicrobial agents and chemotherapy 62 (9), e00012-18, 2018
342018
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine
SP Zvada, P Denti, H Geldenhuys, S Meredith, D van As, M Hatherill, ...
Antimicrobial agents and chemotherapy 56 (8), 4471-4473, 2012
332012
Delayed sputum culture conversion in TB-HIV co-infected patients with low isoniazid and rifampicin concentrations
C Sekaggya-Wiltshire, A von Braun, M Lamorde, B Ledergerber, ...
Clinical Infectious Diseases, 2018
32*2018
A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs
A Daskapan, LR Idrus, MJ Postma, B Wilffert, JGW Kosterink, Y Stienstra, ...
Clinical pharmacokinetics 58 (6), 747-766, 2019
312019
Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis
P Denti, AJ Garcia-Prats, HR Draper, L Wiesner, J Winckler, S Thee, ...
Antimicrobial agents and chemotherapy 62 (2), e01521-17, 2018
312018
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB
A Naidoo, M Chirehwa, H McIlleron, K Naidoo, S Essack, N Yende-Zuma, ...
Journal of Antimicrobial Chemotherapy 72 (5), 1441-1449, 2017
302017
The system can't perform the operation now. Try again later.
Articles 1–20